Given the successful clinical studies on the efficacy of T-DXd in a later-line setting, T-DXd is currently being investigated in the first-line setting versus the standard treatment of chemotherapy plus pembrolizumab in ERBB2-mutated NSCLC in the phase III, DESTINY-Lung04 trial [89]. Here, ERBB2 is linked to non-small cell lung carcinoma.